Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Sales and Divestitures (2016 - 2021)

ImmunityBio (IBRX) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $336084.0 as the latest value for Q2 2021.

  • On a quarterly basis, Gains from Sales and Divestitures fell 39.88% to $336084.0 in Q2 2021 year-over-year; TTM through Jun 2021 was $336084.0, a 39.88% decrease, with the full-year FY2020 number at $648336.0, up 64.11% from a year prior.
  • Gains from Sales and Divestitures was $336084.0 for Q2 2021 at ImmunityBio, up from $235725.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $648336.0 in Q4 2020 to a low of $6625.0 in Q1 2017.
  • A 5-year average of $234234.9 and a median of $172330.0 in 2018 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 93.04% in 2017, then skyrocketed 959.62% in 2018.
  • ImmunityBio's Gains from Sales and Divestitures stood at $244209.0 in 2017, then fell by 29.43% to $172330.0 in 2018, then skyrocketed by 129.24% to $395051.0 in 2019, then soared by 64.11% to $648336.0 in 2020, then tumbled by 48.16% to $336084.0 in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Gains from Sales and Divestitures are $336084.0 (Q2 2021), $235725.0 (Q1 2021), and $648336.0 (Q4 2020).